Fexinidazole

  • TRADE NAME: Fexinidazole (Sanofi)
  • INDICATIONS: Treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis due to Trypanosoma brucei gambiense.
  • SYNONYM: Fexinidazole Winthrop
  • CLASS: Antimicrobial, Antiprotozoal

FDA APPROVAL DATE: 07/16/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Adefovir, Bupropion, Carbamazepine, Cefaclor, Clarithromycin, Diazepam, Dofetilide, Duloxetine, Efavirenz, Erythromycin, Fluconazole, Furosemide, Itraconazole, Lansoprazole, Lovastatin, Mephenytoin, Metformin, Midazolam, Nisoldipine, Phenytoin, Rifampin, Saquinavir, Simvastatin, St John's Wort, Tacrine, Theophylline, Tizanidine, Voriconazole


Insufficient to evaluate for a drug-associated risk of major birth defects or miscarriage.

Avoid concomitant use of herbal medicines and supplements
during treatment with fexinidazole.

Our database has 42 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.


Page last updated 08/26/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top